510(k) device
TriVerity
Inflammatix, Inc. · Rt-Qpcr Assay For Mrna Transcript Immune Biomarkers (PRE, Class II) · First FDA decision Jan 10, 2025, newest Jan 10, 2025Sepsis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "TriVerity"
MAUDE reports
1
Brand "TriVerity", since 2015
PubMed studies
9
Mentioning "TriVerity"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- TriVerityBreakthrough510(k)
K241676 · Decided Jan 10, 2025 · 213 days after receipt
Device type: Rt-Qpcr Assay For Mrna Transcript Immune Biomarkers (PRE) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40470WPS Insurance CorporationUpdated Sep 17, 2026
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40429Palmetto GBAUpdated Aug 21, 2026
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40433CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40435Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "TriVerity", any status and sponsor, newest update first.
No registered device study names "TriVerity".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "TriVerity", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code PRE
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
- MYRNA (TRIVERITY)Malfunction
MW5190807 · Received Jul 16, 2026 · Event dated Jul 1, 2026
Device type: Real Time Nucleic Acid Amplification System (OOI)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "TriVerity"[tiab]. The summary above synthesizes these.
- Comparison of two rapid host-response tests for distinguishing bacterial and viral infection in adults with acute respiratory infection.
Dedeoglu BE, Tanner AR, Brendish NJ, et al. · J Infect · 2024Comparative Study
- Early sepsis recognition: a pilot study using a rapid high-multiplex host-response mRNA diagnostic test.
Lu J, Ter Voert MA, Ünal M, et al. · Intensive Care Med Exp · 2025
- Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis.
Liesenfeld O, Arora S, Aufderheide TP, et al. · Nat Med · 2025Observational Study, Validation Study
- Reduction of resources with mRNA host-response whole blood testing on patients presenting to the emergency department with suspected infections: a retrospective analysis of 30 cases.
Wu AHB, Falcinelli S, Yakubu R · J Med Microbiol · 2025
- 29-mRNA host response signatures for classification of bacterial infection, viral infection and disease progression in COVID-19 pneumonia: a post hoc analysis of the SAVE-MORE randomized clinical trial.
Kyriazopoulou E, Kotsaki A, Safarika A, et al. · Intensive Care Med Exp · 2025
- Host response profiling reveals heterogenous immune responses in hospitalised adults with respiratory viral detection.
Tanner AR, Dedeoglu BE, Brendish NJ, et al. · J Infect · 2026
- Real-world clinical evaluation of the Inflammatix TriVerity test for sepsis at the emergency department: an Acutelines study.
Ter Voert MA, Lu J, Hincapié-Osorno C, et al. · Intern Emerg Med · 2026
- Analytical evaluation of TriVerity, a rapid diagnostic and prognostic host gene expression test performed on the Myrna instrument using RT-LAMP.
Figueiredo-Pereira C, Fleming P, Alganes MN, et al. · J Clin Microbiol · 2025Evaluation Study, Research Support, Non-U.S. Gov't
- Realߛworld clinical evaluation of the Inflammatix TriVerity test for sepsis at the emergency department-an Acutelines study: comment.
Yang L, Lin X · Intern Emerg Med · 2026Letter
Other devices of this type
Also filed under product code PRE.
- SeptiCyte RAPIDImmunexpress, Inc. · 510(k) 2023
- SeptiCyte LABImmunexpress, Inc. · 510(k) 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.